Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
Identifieur interne : 000240 ( PubMed/Corpus ); précédent : 000239; suivant : 000241Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
Auteurs : Kim H Rslev-Petersen ; Merete Lund Hetland ; Peter Junker ; Jan P Denphant ; Torkell Ellingsen ; Palle Ahlquist ; Hanne Lindegaard ; Asta Linauskas ; Annette Schlemmer ; Mette Yde Dam ; Ib Hansen ; Hans Christian Horn ; Christian Gytz Ammitzb Ll ; Anette J Rgensen ; Sophine B. Krintel ; Johnny Raun ; Julia S. Johansen ; Mikkel Stergaard ; Kristian Stengaard-PedersenSource :
- Annals of the rheumatic diseases ; 2014.
English descriptors
- KwdEn :
- Adalimumab, Adult, Aged, Antibodies, Monoclonal, Humanized (administration & dosage), Antibodies, Monoclonal, Humanized (adverse effects), Antibodies, Monoclonal, Humanized (therapeutic use), Antirheumatic Agents (administration & dosage), Antirheumatic Agents (adverse effects), Antirheumatic Agents (therapeutic use), Arthritis, Rheumatoid (drug therapy), Arthritis, Rheumatoid (physiopathology), Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Injections, Intra-Articular, Male, Methotrexate (administration & dosage), Methotrexate (adverse effects), Methotrexate (therapeutic use), Middle Aged, Quality of Life, Remission Induction, Severity of Illness Index, Treatment Outcome, Triamcinolone (administration & dosage), Triamcinolone (adverse effects), Triamcinolone (therapeutic use).
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Methotrexate, Triamcinolone.
- chemical , adverse effects : Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Methotrexate, Triamcinolone.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Methotrexate, Triamcinolone.
- chemical : Adalimumab.
- drug therapy : Arthritis, Rheumatoid.
- physiopathology : Arthritis, Rheumatoid.
- Adult, Aged, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Injections, Intra-Articular, Male, Middle Aged, Quality of Life, Remission Induction, Severity of Illness Index, Treatment Outcome.
Abstract
An investigator-initiated, double-blinded, placebo-controlled, treat-to-target protocol (Clinical Trials:NCT00660647) studied whether adalimumab added to methotrexate and intra-articular triamcinolone as first-line treatment in early rheumatoid arthritis (ERA) increased the frequency of low disease activity (DAS28CRP<3.2) at 12 months.
DOI: 10.1136/annrheumdis-2012-202735
PubMed: 23434570
Links to Exploration step
pubmed:23434570Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.</title><author><name sortKey="H Rslev Petersen, Kim" sort="H Rslev Petersen, Kim" uniqKey="H Rslev Petersen K" first="Kim" last="H Rslev-Petersen">Kim H Rslev-Petersen</name><affiliation><nlm:affiliation>Department of Rheumatology, King Christian 10th Hospital for Rheumatic Diseases, , Gråsten, Denmark; South Jutland Hospital, Institute of Regional Health Services Research, University of Southern Denmark, , Odense, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Hetland, Merete Lund" sort="Hetland, Merete Lund" uniqKey="Hetland M" first="Merete Lund" last="Hetland">Merete Lund Hetland</name></author><author><name sortKey="Junker, Peter" sort="Junker, Peter" uniqKey="Junker P" first="Peter" last="Junker">Peter Junker</name></author><author><name sortKey="P Denphant, Jan" sort="P Denphant, Jan" uniqKey="P Denphant J" first="Jan" last="P Denphant">Jan P Denphant</name></author><author><name sortKey="Ellingsen, Torkell" sort="Ellingsen, Torkell" uniqKey="Ellingsen T" first="Torkell" last="Ellingsen">Torkell Ellingsen</name></author><author><name sortKey="Ahlquist, Palle" sort="Ahlquist, Palle" uniqKey="Ahlquist P" first="Palle" last="Ahlquist">Palle Ahlquist</name></author><author><name sortKey="Lindegaard, Hanne" sort="Lindegaard, Hanne" uniqKey="Lindegaard H" first="Hanne" last="Lindegaard">Hanne Lindegaard</name></author><author><name sortKey="Linauskas, Asta" sort="Linauskas, Asta" uniqKey="Linauskas A" first="Asta" last="Linauskas">Asta Linauskas</name></author><author><name sortKey="Schlemmer, Annette" sort="Schlemmer, Annette" uniqKey="Schlemmer A" first="Annette" last="Schlemmer">Annette Schlemmer</name></author><author><name sortKey="Dam, Mette Yde" sort="Dam, Mette Yde" uniqKey="Dam M" first="Mette Yde" last="Dam">Mette Yde Dam</name></author><author><name sortKey="Hansen, Ib" sort="Hansen, Ib" uniqKey="Hansen I" first="Ib" last="Hansen">Ib Hansen</name></author><author><name sortKey="Horn, Hans Christian" sort="Horn, Hans Christian" uniqKey="Horn H" first="Hans Christian" last="Horn">Hans Christian Horn</name></author><author><name sortKey="Ammitzb Ll, Christian Gytz" sort="Ammitzb Ll, Christian Gytz" uniqKey="Ammitzb Ll C" first="Christian Gytz" last="Ammitzb Ll">Christian Gytz Ammitzb Ll</name></author><author><name sortKey="J Rgensen, Anette" sort="J Rgensen, Anette" uniqKey="J Rgensen A" first="Anette" last="J Rgensen">Anette J Rgensen</name></author><author><name sortKey="Krintel, Sophine B" sort="Krintel, Sophine B" uniqKey="Krintel S" first="Sophine B" last="Krintel">Sophine B. Krintel</name></author><author><name sortKey="Raun, Johnny" sort="Raun, Johnny" uniqKey="Raun J" first="Johnny" last="Raun">Johnny Raun</name></author><author><name sortKey="Johansen, Julia S" sort="Johansen, Julia S" uniqKey="Johansen J" first="Julia S" last="Johansen">Julia S. Johansen</name></author><author><name sortKey=" Stergaard, Mikkel" sort=" Stergaard, Mikkel" uniqKey=" Stergaard M" first="Mikkel" last=" Stergaard">Mikkel Stergaard</name></author><author><name sortKey="Stengaard Pedersen, Kristian" sort="Stengaard Pedersen, Kristian" uniqKey="Stengaard Pedersen K" first="Kristian" last="Stengaard-Pedersen">Kristian Stengaard-Pedersen</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:23434570</idno><idno type="pmid">23434570</idno><idno type="doi">10.1136/annrheumdis-2012-202735</idno><idno type="wicri:Area/PubMed/Corpus">000240</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.</title><author><name sortKey="H Rslev Petersen, Kim" sort="H Rslev Petersen, Kim" uniqKey="H Rslev Petersen K" first="Kim" last="H Rslev-Petersen">Kim H Rslev-Petersen</name><affiliation><nlm:affiliation>Department of Rheumatology, King Christian 10th Hospital for Rheumatic Diseases, , Gråsten, Denmark; South Jutland Hospital, Institute of Regional Health Services Research, University of Southern Denmark, , Odense, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Hetland, Merete Lund" sort="Hetland, Merete Lund" uniqKey="Hetland M" first="Merete Lund" last="Hetland">Merete Lund Hetland</name></author><author><name sortKey="Junker, Peter" sort="Junker, Peter" uniqKey="Junker P" first="Peter" last="Junker">Peter Junker</name></author><author><name sortKey="P Denphant, Jan" sort="P Denphant, Jan" uniqKey="P Denphant J" first="Jan" last="P Denphant">Jan P Denphant</name></author><author><name sortKey="Ellingsen, Torkell" sort="Ellingsen, Torkell" uniqKey="Ellingsen T" first="Torkell" last="Ellingsen">Torkell Ellingsen</name></author><author><name sortKey="Ahlquist, Palle" sort="Ahlquist, Palle" uniqKey="Ahlquist P" first="Palle" last="Ahlquist">Palle Ahlquist</name></author><author><name sortKey="Lindegaard, Hanne" sort="Lindegaard, Hanne" uniqKey="Lindegaard H" first="Hanne" last="Lindegaard">Hanne Lindegaard</name></author><author><name sortKey="Linauskas, Asta" sort="Linauskas, Asta" uniqKey="Linauskas A" first="Asta" last="Linauskas">Asta Linauskas</name></author><author><name sortKey="Schlemmer, Annette" sort="Schlemmer, Annette" uniqKey="Schlemmer A" first="Annette" last="Schlemmer">Annette Schlemmer</name></author><author><name sortKey="Dam, Mette Yde" sort="Dam, Mette Yde" uniqKey="Dam M" first="Mette Yde" last="Dam">Mette Yde Dam</name></author><author><name sortKey="Hansen, Ib" sort="Hansen, Ib" uniqKey="Hansen I" first="Ib" last="Hansen">Ib Hansen</name></author><author><name sortKey="Horn, Hans Christian" sort="Horn, Hans Christian" uniqKey="Horn H" first="Hans Christian" last="Horn">Hans Christian Horn</name></author><author><name sortKey="Ammitzb Ll, Christian Gytz" sort="Ammitzb Ll, Christian Gytz" uniqKey="Ammitzb Ll C" first="Christian Gytz" last="Ammitzb Ll">Christian Gytz Ammitzb Ll</name></author><author><name sortKey="J Rgensen, Anette" sort="J Rgensen, Anette" uniqKey="J Rgensen A" first="Anette" last="J Rgensen">Anette J Rgensen</name></author><author><name sortKey="Krintel, Sophine B" sort="Krintel, Sophine B" uniqKey="Krintel S" first="Sophine B" last="Krintel">Sophine B. Krintel</name></author><author><name sortKey="Raun, Johnny" sort="Raun, Johnny" uniqKey="Raun J" first="Johnny" last="Raun">Johnny Raun</name></author><author><name sortKey="Johansen, Julia S" sort="Johansen, Julia S" uniqKey="Johansen J" first="Julia S" last="Johansen">Julia S. Johansen</name></author><author><name sortKey=" Stergaard, Mikkel" sort=" Stergaard, Mikkel" uniqKey=" Stergaard M" first="Mikkel" last=" Stergaard">Mikkel Stergaard</name></author><author><name sortKey="Stengaard Pedersen, Kristian" sort="Stengaard Pedersen, Kristian" uniqKey="Stengaard Pedersen K" first="Kristian" last="Stengaard-Pedersen">Kristian Stengaard-Pedersen</name></author></analytic><series><title level="j">Annals of the rheumatic diseases</title><idno type="e-ISSN">1468-2060</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adalimumab</term><term>Adult</term><term>Aged</term><term>Antibodies, Monoclonal, Humanized (administration & dosage)</term><term>Antibodies, Monoclonal, Humanized (adverse effects)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antirheumatic Agents (administration & dosage)</term><term>Antirheumatic Agents (adverse effects)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Arthritis, Rheumatoid (physiopathology)</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Injections, Intra-Articular</term><term>Male</term><term>Methotrexate (administration & dosage)</term><term>Methotrexate (adverse effects)</term><term>Methotrexate (therapeutic use)</term><term>Middle Aged</term><term>Quality of Life</term><term>Remission Induction</term><term>Severity of Illness Index</term><term>Treatment Outcome</term><term>Triamcinolone (administration & dosage)</term><term>Triamcinolone (adverse effects)</term><term>Triamcinolone (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term><term>Methotrexate</term><term>Triamcinolone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term><term>Methotrexate</term><term>Triamcinolone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term><term>Methotrexate</term><term>Triamcinolone</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Adalimumab</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Injections, Intra-Articular</term><term>Male</term><term>Middle Aged</term><term>Quality of Life</term><term>Remission Induction</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">An investigator-initiated, double-blinded, placebo-controlled, treat-to-target protocol (Clinical Trials:NCT00660647) studied whether adalimumab added to methotrexate and intra-articular triamcinolone as first-line treatment in early rheumatoid arthritis (ERA) increased the frequency of low disease activity (DAS28CRP<3.2) at 12 months.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">23434570</PMID><DateCreated><Year>2014</Year><Month>02</Month><Day>28</Day></DateCreated><DateCompleted><Year>2014</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-2060</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Annals of the rheumatic diseases</Title><ISOAbbreviation>Ann. Rheum. Dis.</ISOAbbreviation></Journal><ArticleTitle>Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.</ArticleTitle><Pagination><MedlinePgn>654-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/annrheumdis-2012-202735</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">An investigator-initiated, double-blinded, placebo-controlled, treat-to-target protocol (Clinical Trials:NCT00660647) studied whether adalimumab added to methotrexate and intra-articular triamcinolone as first-line treatment in early rheumatoid arthritis (ERA) increased the frequency of low disease activity (DAS28CRP<3.2) at 12 months.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In 14 Danish hospital-based clinics, 180 disease-modifying anti-rheumatic drugs (DMARD)-naïve ERA patients (<6 months duration) received methotrexate 7.5 mg/week (increased to 20 mg/week within 2 months) plus adalimumab 40 mg every other week (adalimumab-group, n=89) or methotrexate+placebo-adalimumab (placebo-group, n=91). At all visits, triamcinolone was injected into swollen joints (max. four joints/visit). If low disease activity was not achieved, sulfasalazine 2 g/day and hydroxychloroquine 200 mg/day were added after 3 months, and open-label biologics after 6-9 months. Efficacy was assessed primarily on the proportion of patients who reached treatment target (DAS28CRP<3.2). Secondary endpoints included DAS28CRP, remission, Health Assessment Questionnaire (HAQ), EQ-5D and SF-12. Analysis was by intention-to-treat with last observation carried forward.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline characteristics were similar between groups. In the adalimumab group/placebo group the 12-month cumulative triamcinolone doses were 5.4/7.0 ml (p=0.08). Triple therapy was applied in 18/27 patients (p=0.17). At 12 months, DAS28CRP<3.2 was reached in 80%/76% (p=0.65) and DAS28CRP was 2.0 (1.7-5.2) (medians (5th/95th percentile ranges)), versus 2.6 (1.7-4.7) (p=0.009). Remission rates were: DAS28CRP<2.6: 74%/49%, Clinical Disease Activity Index≤2.8: 61%/41%, Simplified Disease Activity Index<3.3: 57%/37%, European League Against Rheumatism/American College of Rheumatology Boolean: 48%/30% (0.0008</AbstractText> <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Adalimumab added to methotrexate and intra-articular triamcinolone as first-line treatment did not increase the proportion of patients who reached the DAS28CRP<3.2 treatment target, but improved DAS28CRP, remission rates, function and quality of life in DMARD-naïve ERA.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hørslev-Petersen</LastName><ForeName>Kim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, King Christian 10th Hospital for Rheumatic Diseases, , Gråsten, Denmark; South Jutland Hospital, Institute of Regional Health Services Research, University of Southern Denmark, , Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hetland</LastName><ForeName>Merete Lund</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Junker</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Pødenphant</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ellingsen</LastName><ForeName>Torkell</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Ahlquist</LastName><ForeName>Palle</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lindegaard</LastName><ForeName>Hanne</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Linauskas</LastName><ForeName>Asta</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Schlemmer</LastName><ForeName>Annette</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Dam</LastName><ForeName>Mette Yde</ForeName><Initials>MY</Initials></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>Ib</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Horn</LastName><ForeName>Hans Christian</ForeName><Initials>HC</Initials></Author><Author ValidYN="Y"><LastName>Ammitzbøll</LastName><ForeName>Christian Gytz</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Jørgensen</LastName><ForeName>Anette</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Krintel</LastName><ForeName>Sophine B</ForeName><Initials>SB</Initials></Author><Author ValidYN="Y"><LastName>Raun</LastName><ForeName>Johnny</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Johansen</LastName><ForeName>Julia S</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Østergaard</LastName><ForeName>Mikkel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Stengaard-Pedersen</LastName><ForeName>Kristian</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><CollectiveName>OPERA Study-Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>02</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Rheum Dis</MedlineTA><NlmUniqueID>0372355</NlmUniqueID><ISSNLinking>0003-4967</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>1ZK20VI6TY</RegistryNumber><NameOfSubstance UI="D014221">Triamcinolone</NameOfSubstance></Chemical><Chemical><RegistryNumber>FYS6T7F842</RegistryNumber><NameOfSubstance UI="D000068879">Adalimumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000068879">Adalimumab</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018501">Antirheumatic Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001172">Arthritis, Rheumatoid</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007270">Injections, Intra-Articular</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008727">Methotrexate</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011788">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012074">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014221">Triamcinolone</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Corticosteroids</Keyword><Keyword MajorTopicYN="N">DMARDs (biologic)</Keyword><Keyword MajorTopicYN="N">DMARDs (synthetic)</Keyword><Keyword MajorTopicYN="N">Disease Activity</Keyword><Keyword MajorTopicYN="N">Early Rheumatoid Arthritis</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Slot</LastName><ForeName>Ole</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Lars Kjær</ForeName><Initials>LK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Skjødt</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Majgaard</LastName><ForeName>Ole</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lorenzen</LastName><ForeName>Tove</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kowalski</LastName><ForeName>Marcin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johansen</LastName><ForeName>Inger Lauge</ForeName><Initials>IL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pedersen</LastName><ForeName>Peter Mosborg</ForeName><Initials>PM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manilo</LastName><ForeName>Natalia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bliddal</LastName><ForeName>Henning</ForeName><Initials>H</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="aheadofprint"><Year>2013</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2013</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23434570</ArticleId><ArticleId IdType="pii">annrheumdis-2012-202735</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2012-202735</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000240 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000240 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Musique
|area= OperaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:23434570
|texte= Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:23434570" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a OperaV1
| This area was generated with Dilib version V0.6.21. |  |